Analyst Price Targets — CSTL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 29, 2026 8:40 pm | Paul Knight | KeyBanc | $50.00 | $39.16 | TheFly | Castle Biosciences price target raised to $50 from $36 at KeyBanc |
| January 26, 2026 2:35 pm | Subbu Nambi | Guggenheim | $47.00 | $43.08 | TheFly | Castle Biosciences price target raised to $47 from $43 at Guggenheim |
| January 12, 2026 2:17 pm | — | Lake Street | $52.00 | $40.14 | TheFly | Castle Biosciences price target raised to $52 from $35 at Lake Street |
| January 5, 2026 2:26 pm | — | Guggenheim | $43.00 | $37.77 | TheFly | Castle Biosciences price target raised to $43 from $30 at Guggenheim |
| December 22, 2025 11:54 am | — | Canaccord Genuity | $50.00 | $39.44 | TheFly | Castle Biosciences price target raised to $50 from $37 at Canaccord |
| December 12, 2025 12:23 pm | Mark Massaro | BTIG | $50.00 | $37.97 | TheFly | Castle Biosciences price target raised to $50 from $38 at BTIG |
| March 28, 2025 11:10 am | Subbu Nambi | Guggenheim | $30.00 | $20.10 | TheFly | Castle Biosciences price target lowered to $30 from $37 at Guggenheim |
| February 28, 2025 12:58 pm | — | Robert W. Baird | $37.00 | $21.68 | TheFly | Castle Biosciences price target raised to $37 from $36 at Baird |
| November 5, 2024 8:50 pm | Sung Ji Nam | BTIG | $45.00 | $31.15 | StreetInsider | Castle Biosciences (CSTL) PT Raised to $45 at BTIG |
| November 5, 2024 11:50 am | Catherine Schulte | Robert W. Baird | $39.00 | $32.80 | StreetInsider | Castle Biosciences (CSTL) PT Raised to $39 at Baird |
Latest News for CSTL
FRIENDSWOOD, Texas, April 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2026, after the close of market on Wednesday, May 6, 2026. Company management will host a webcast to discuss its financial results at 4:30 p.m.
FRIENDSWOOD, Texas, April 10, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received the 2026 USA TODAY Top Workplaces USA Award for the fifth consecutive year. The national award program by Energage and USA TODAY celebrates organizations with 150 or more employees that have built exceptional,…
Castle Biosciences, Inc. is positioned as a leader in precision cancer diagnostics, notably with DecisionDx-Melanoma, offering scalable, clinically validated solutions. CSTL reported strong Q4/FY2025 revenue growth and robust cash reserves but faces a projected EPS decline in 2026 as it invests aggressively in growth and commercialization. DecisionDx-Melanoma stands out as a de-risked, durable growth driver with…
Data from 1,868 Surveillance, Epidemiology and End Results (SEER)-linked patients show DecisionDx-Melanoma significantly stratifies five-year melanoma-specific survival within American Joint Committee on Cancer (AJCC) stages and T categories, identifying patients whose mortality risk is substantially higher or lower than staging alone would predict FRIENDSWOOD, Texas, March 27, 2026 /PRNewswire/ -- Castle…
Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CSTL.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.